Hostname: page-component-7b9c58cd5d-7g5wt Total loading time: 0 Render date: 2025-03-16T00:28:33.226Z Has data issue: false hasContentIssue false

Treatment with recombinant human tumour necrosis factor-α reduces parasitaemia and prevents Plasmodium berghei K173-induced experimental cerebral malaria in mice

Published online by Cambridge University Press:  01 January 1999

N. S. POSTMA
Affiliation:
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
C. C. HERMSEN
Affiliation:
Department of Medical Microbiology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
D. J. A. CROMMELIN
Affiliation:
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
J. ZUIDEMA
Affiliation:
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands
W. M. C. ELING
Affiliation:
Department of Medical Microbiology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The present study shows that treatment with recombinant human tumour necrosis factor-α (rhTNF-α) can suppress parasitaemia and prevents development of experimental cerebral malaria (ECM) in Plasmodium berghei K173-infected mice. Mice received rhTNF-α treatment either by subcutaneous injection of free or liposome-encapsulated rhTNF-α or sustained intraperitoneal administration of rhTNF-α given via mini-osmotic pumps. Low-dose treatment with a subcutaneous bolus injection of rhTNF-α protected against ECM when treatment was started on day 5 or 6 after infection. The same protective efficacy was obtained either by subcutaneous injection of liposome-encapsulated rhTNF-α or by sustained release from osmotic pumps, but in the latter case a 10-fold lower daily dose of rhTNF-α was sufficient. Treatment with rhTNF-α substantially suppressed parasitaemia in ECM-protected mice, but not in mice developing ECM. Thus, the rhTNF-α mediated suppression of parasitaemia is directly or indirectly involved in protection against ECM. Sustained delivery of rhTNF-α through osmotic pumps, but not by subcutaneous injection of liposome-encapsulated rhTNF-α, resulted in increased concentrations of soluble mouse TNF receptor R75 (sTNFR75) in plasma at day 9 after infection when non-treated mice die of ECM. Thus, protection against ECM is not directly correlated with the sTNFR75 concentrations at day 9 after infection.

Type
Research Article
Copyright
1999 Cambridge University Press